1-3 of 3
Pil Kim
Close
Sort by
Journal Articles

Health-Related Quality of Life (HRQoL) in Patients with Relapsed/Refractory Follicular Lymphoma (R/R FL) Treated with Zanubrutinib+ Obinutuzumab Versus Obinutuzumab Monotherapy: The Rosewood Trial

Judith Trotman, Pier Luigi Zinzani, Yuqin Song, Richard Delarue, Gisoo Barnes, Pil Kim, Elena Ivanova, Boxiong Tang, Jiří Mayer, Ana C. De Oliveira, Sarit Assouline, Christopher R. Flowers
Journal: Blood
Blood (2023) 142 (Supplement 1): 1674.
https://doi.org/10.1182/blood-2023-181195
Published: 2023
Journal Articles

Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study

Clinical Trials & Observations
Yuqin Song, Keshu Zhou, Dehui Zou, Jianfeng Zhou, Jianda Hu, Haiyan Yang, Huilai Zhang, Jie Ji, Wei Xu, Jie Jin, Fangfang Lv, Ru Feng, Sujun Gao, Haiyi Guo, Lei Zhou, Jane Huang, William Novotny, Pil Kim, Yiling Yu, Binghao Wu, Jun Zhu
Journal: Blood
Blood (2022) 139 (21): 3148–3158.
https://doi.org/10.1182/blood.2021014162
Published: 2022
Includes: Supplemental data
Journal Articles

Open-Label, Multicenter, Phase 2/3 Study of Recombinant Crisantaspase Produced in Pseudomonas Fluorescens ( RC-P) in Patients with Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) Following Hypersensitivity to Escherichia coli -Derived Asparaginases

Luke Maese, DO, Rachel E. Rau, MD, Elizabeth A. Raetz, MD, Tong Lin, Jin Zhu, Pil Kim, Reddy Chandula, Sherrie McClung, Julie Gray, Mi Rim Choi, MD, Mignon L. Loh, MD, Peter C. Adamson
Journal: Blood
Blood (2019) 134 (Supplement_1): 2586.
https://doi.org/10.1182/blood-2019-123710
Published: 2019